drugset / Trial / NCT02328443
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
Non-randomizedSingle-groupOpen-labelBasic science
Summary
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Midazolam | Small molecule | — | Intravenous |
| Subject | Rifampicin | Small molecule | 150 mg | Oral |
Indications
No indication recorded.